EP₄ receptor as a new target for bronchodilator therapy

James Buckley,¹ Mark A Birrell,¹ Sarah A Maher,¹ Anthony T Nials,² Deborah L Clarke,¹ Maria G Belvisi¹

ABSTRACT

Background Asthma and chronic obstructive pulmonary disease are airway inflammatory diseases characterised by airflow obstruction. Currently approved bronchodilators such as long-acting β₂ adrenoceptor agonists are the mainstay treatments but often fail to relieve symptoms of chronic obstructive pulmonary disease and severe asthma and safety concerns have been raised over long-term use. The aim of the study was to identify the receptor involved in prostaglandin E₂ (PGE₂)-induced relaxation in guinea pig, murine, monkey, rat and human airways in vitro.

Methods Using an extensive range of pharmacological tools, the relaxant potential of PGE₂ and selective agonists for the EP₁-₄ receptors in the presence and absence of selective antagonists in guinea pig, murine, monkey, rat and human isolated airways was investigated.

Results In agreement with previous studies, it was found that the EP₂ receptor mediates PGE₂-induced relaxation of guinea pig, murine and monkey trachea and that the EP₄ receptor mediates PGE₂-induced relaxation of the rat trachea. These data have been confirmed in murine airways from EP₂ receptor-deficient mice (Ptger2). In contrast to previous publications, a role for the EP₄ receptor in relaxant responses in human airways in vitro was found. Relaxant activity of AH13205 (EP₄ agonist) was also demonstrated in guinea pig but not human airway tissue, which may explain its failure in clinical studies.

Conclusion Identification of the receptor mediating PGE₂-induced relaxation represents a key step in developing a novel bronchodilator therapy. These data explain the lack of bronchodilator activity observed with selective EP₂ receptor agonists in clinical studies.

INTRODUCTION

Asthma and chronic obstructive pulmonary disease (COPD) are inflammatory diseases of the airway characterised by airflow limitation. The Global Burden of Disease Study¹ has projected that COPD, which ranked sixth as the cause of death in 1990, will become the third leading cause of death worldwide by 2020. Globally, approximately 300 million people have asthma, which is the most common chronic disease in children.² ³

Currently, the majority of patients with inflammatory diseases of the airway are treated with a combination of long-acting β agonists (LABAs) and corticosteroids, but significant issues exist with these therapies, particularly LABAs. While long- and short-acting β agonists help to provide patients with short-term relief from airflow limitation, they do little to treat the underlying pathology. Furthermore, since the introduction of LABAs, there has been increasing concern that their use may be associated with an increased risk of death from asthma.⁴

A number of clinical studies have reported beneficial effects of inhaled PGE₂ on airway calibre in normal subjects and patients with asthma and COPD, and we have identified a role for the EP₄ receptor in these relaxant responses.

Key messages

What is the key question?

New bronchodilator therapies are needed, given that currently approved bronchodilators such as long-acting β₂ adrenoceptor agonists often fail to relieve symptoms of COPD and severe asthma and safety concerns have been raised over long-term use.

What is the bottom line?

A number of clinical studies have reported beneficial effects of inhaled prostaglandin E₂ (PGE₂) on airway calibre in normal subjects⁵–⁷ and in patients with chronic bronchitis and asthma.⁸ ⁹ ¹⁰ In addition, PGE₂ has anti-inflammatory properties in patients with asthma,¹¹ providing an ideal dual therapy for the treatment of these diseases. Despite the benefits of inhaled PGE₂, the development of prostanoid agonists for the treatment of airway inflammatory diseases has been hindered as prostanoids induce irritancy of the upper airway resulting in a reflex cough.¹¹ PGE₂ can act on a number of receptors, so it was hoped that the beneficial bronchodilator and anti-inflammatory effects could be dissociated from the airway irritancy to provide a novel therapeutic target.

There are currently nine known prostanoid receptors. PGE₂ has relatively low affinity for the FP, IP, TP, DP and CRTh2 receptors and acts predominantly via the EP receptors. The EP receptors have been subclassified into EP₁, EP₂, EP₃ and EP₄ (encoded by Ptger₁–Ptger₄ genes)¹²–¹⁴ and distinct signalling pathways initiate diverse and opposing downstream effects in different...
tissues. Several investigators have documented bronchodilator activity in vitro and in vivo in a wide range of species including guinea pigs, mice and humans, and it has been suggested that EP2 receptor activation is responsible for PGE2 activity. However, a selective EP2 receptor agonist (AH115205) with a promising preclinical profile did not appear to have any bronchodilator activity in man. Previous studies have been hampered by the lack of selective pharmacological tools. We now have a wide range of tool compounds and, by adopting a pharmacological approach and prostanoid receptor-deficient mice, we provide substantial evidence that, although the EP2 receptor mediates PGE2-induced relaxation in several species, it is in fact the EP4 receptor that mediates relaxation of human airways. This is an important finding which could lead to the development of a new class of bronchodilator therapy.

METHODS

Male C57BL/6 mice (18–20 g), Dunkin-Hartley guinea pigs (500–500 g) and Cynomolgus (Cyno) monkey (Macaca fascicularis) tissue were purchased from Harlan (Bicester, Oxon, UK) and male Sprague Dawley rats (250–275 g) were purchased from Charles River (Margate, UK). EP receptor gene-deleted mice were originally provided by Dr Shuh Narumiya, Kyoto University and breeding colonies were maintained at Imperial College, London. Human airway samples (trachea, major bronchus, secondary bronchi) were obtained from donor patients (n = 80) (apart from murine) was opened longitudinally by cutting through the cartilage directly opposite to the smooth muscle layer. Unless stated otherwise, the epithelium was left intact and transverse segments were prepared and sutured in order to be suspended from steel hook transducers in 10 ml baths containing Krebs—Henseleit (KH) solution warmed to 37°C and bubbled with 95% O2/5% CO2. Indomethacin (10 μM), a non-selective COX inhibitor, was present in KH solution in all experiments to prevent the production and release of endogenous prostanooids. Changes in force were measured isometrically using force displacement transducers connected to a data acquisition system as previously described.

Carbachol (CCh; 1 μM) was used to induce increased tension in tissues over a 30 min period before the addition of any antagonists or their appropriate vehicles which were incubated for a further 30 min. This concentration of CCh was required to produce approximately 80% of the supramaximal response to 1 mM ACh in all species. Cumulative concentration–response curves were then constructed using the relevant drugs and subsequently, at the end of the experiment, the non-specific phosphodiesterase inhibitor papaverine (100 μM) was used to assess the maximum capacity for relaxation of each tissue. For experiments on smaller airways, third to fourth generation bronchi (1–2 mm diameter) were dissected and sutured as described. For these experiments, a higher concentration of CCh (10 μM) was necessary to induce the required level of increased tension.

Full details are given in the online supplement.

Data analysis and statistics

Data are expressed as mean±SEM of n independent observations. Concentration–response curves were analysed by non-linear regression using the PRISM curve-fitting program to produce curves of best fit, from which EC50 values were subsequently derived. Estimates of antagonist affinity were calculated using the equation pKb = log (CR – 1) – log [B] as described by Caddum, where CR is the concentration ratio calculated from the EC50 of agonist in the presence of the antagonist divided by the EC50 of the agonist alone, Kb is the equilibrium dissociation constant and [B] is the concentration of antagonist. In the experiments described here, the term pA2 is substituted for pKb as antagonists were used at one concentration only, which precludes assumptions being made about the nature of the antagonism.

RESULTS

Effect of PGE2 on guinea pig tracheal strips

Under basal levels of tension (basal tone), increasing concentrations of PGE2 (0.1 nM–10 μM) resulted in a biphasic response producing a pronounced contraction at lower concentrations (35.4±4.0% of the maximum contraction to ACh, 10 nM) that was later attenuated by increasing the concentration of PGE2 in the bath (figure 1A). This contractile response was completely absent in the presence of the EP1 antagonist GW848687X (1 μM). This was then confirmed using selective EP receptor agonists, with the EP1 selective agonist ONO-D1-004 being the most potent and effective at inducing contraction of the guinea pig trachea (figure 1B).

When tension was induced in the guinea pig trachea using CCh (1 μM) (induced tone), increasing concentrations of PGE2 (0.1 nM–10 μM) produced substantial relaxation (69.1±7.3% of the maximum relaxation to 100 μM papaverine). Due to the apparent contractile actions of PGE2 via the EP1 receptor, PGE2-induced relaxation in guinea pig trachea was performed in the presence of GW848687X (1 μM). Under these conditions, compared to its vehicle control, addition of AH6809 (10 μM) to the bath before the administration of PGE2 antagonised the relaxation produced (figure 1C), resulting in a rightward shift in the curve (pA2=5.7) commensurate with an action at the EP2 receptor (previous studies report antagonist affinities of approximately 5.9–6.3). Subsequently, the response to PGE2 was also assessed in the presence of selective antagonists for EP1, EP2, IP and FP receptors (L-826266, 1 μM; GW627366X, 1 μM; ROS244794, 10 μM; and AL-8810, 10 μM, respectively). Compared with their vehicle controls, addition of these antagonists did not produce any effect on PGE2-induced relaxation in guinea pig tracheal strips (figures not shown). When increasing concentrations of each EP receptor agonist (0.1 nM–1 μM) was applied to guinea pig tissue, only the EP2 agonist ONO-AE1-259 induced substantial relaxation (52.8±3.6% of the maximum relaxation to 100 μM papaverine) (figure 1D). These data, alongside the AH6809 data, indicate that the EP2 receptor mediates PGE2-induced relaxation in guinea pig trachea consistent with previous data.

Effect of PGE2 on murine tracheal segments

In contrast to the guinea pig, the addition of increasing concentrations of PGE2 to mouse tracheal tissue under basal tone failed to produce a contractile response (data not shown). However, when applied to murine tracheal segments under induced tone, PGE2 induced a substantial relaxation response in the tissue (92.6±3.1% of the maximum response to 100 μM papaverine) (figure 2A). This response to PGE2 observed in tissue taken from C57BL/6 wild type mice was then compared with that produced in tissue from prostanoid receptor gene-deficient mice. Of the gene-deleted tissues tested (deficient for EP1, EP2,
EP3, EP4, IP, FP, DP1 or TP receptors), only the response of tracheal segments taken from Ptger2 (EP2)-deficient mice differed substantially from tissue taken from wild type equivalents (figure 2C,D). The relaxation response produced by PGE2 in Ptger2+/− tracheal tissue was substantially reduced (24.5±6.6% of the maximum response to 100 μM papaverine), indicating that PGE2-induced relaxation in mouse tracheal tissue is largely dependent on EP2 receptors. Furthermore, AH6809 antagonised PGE2-induced relaxation in mouse tracheal segments under induced tone, producing a rightward shift in the curve (pA2=5.9) commensurate with affinity at the EP2 receptor (figure 2B).

Interestingly, there was a small reduction in the relaxation produced by PGE2 in IP receptor-deficient tissues (72.0±5.8% of the maximum response to 100 μM papaverine vs 85.9±1.8% for the wild type control), possibly indicating a minor role for the IP receptor in PGE2-induced relaxation in mouse tracheal segments.

The maximum contractile responses to ACh and the maximum relaxation responses to papaverine were not changed in the prostanoid receptor deficient animals.

**Effect of PGE2 on rat tracheal strips**
PGE2 (1 nM–10 μM) did not induce a contractile response in rat tracheal strips under basal tone. However, under induced tone, PGE2 produced a concentration-dependent relaxation although...
smaller in magnitude than in other species (31.9±1.5% of the maximum response to 100 μM papaverine). EP receptor selective agonists (1 nM—10 μM) were evaluated and only the EP4 agonist ONO-AE1-329 caused substantial relaxation (36.7±4.0% of maximum relaxation to 100 μM papaverine) (figure 3A). Furthermore, two structurally distinct EP4 antagonists inhibited PGE2-induced relaxation compared with their vehicle control (0.1% DMSO) (figure 3B). Both GW627368X (1 μM) and ONO-AE3-208 (100 μM) produced a substantial rightward shift in the curve (pA2=6.5±0.1 and 8.9±0.1, respectively) compared with ONO-AE3-208 (100 nM) and GW62768X (1 μM)—failed to produce any significant relaxation (figures 4A and 5B). In experiments on human tissue we used the tool compound with the most optimal profile with regard to antagonist affinity and selectivity (ONO-AE3-208).26 The EP4 antagonist ONO-AE3-208 (100 nM) inhibited both PGE2- and ONO-AE1-329-induced relaxation (pA2=8.0±0.2 and 8.7±0.3, respectively; figure 4C,D). Experiments comparing PGE2 with ONO-AE3-208 in human tissue were conducted in the presence of SQ29548 (TP antagonist, 1 μM) to prevent PGE2-induced contraction via TP receptors. The relaxation response to ONO-AE3-208 was also tested against an alternative non-muscarinic spasmogen. In the presence of 10 μM histamine-induced tone, ONO-AE3-208 still produced substantial relaxation (63.4±19.6% of maximum relaxation to papaverine, logEC50=−7.6±0.5). To ensure the EP4-induced relaxation was not specific to larger airways and not subject to regional differences in the airways, the effect of PGE2, ONO-AE1-259 and ONO-AE3-208 was measured in smaller calibre airways (third to fourth generation bronchi, 1–2 mm diameter). Responses in these airways were similar to those seen in trachea/primary bronchi with PGE2 and ONO-AE1-329 producing relaxation (PGE2: 43.1±5.4% of maximum relaxation to papaverine, logEC50=−7.2 (n=2); ONO-AE3-208: 52.1±5.0% of maximum relaxation to papaverine, logEC50=−7.6±0.1 (n=3)), with ONO-AE1-329 having no substantial effect.

Finally, in order to confirm that the biological activity of AH15205 was similar to that observed in previous studies, we demonstrated its relaxant activity in guinea pig trachea studies (figure 5A).15 However, this relaxant activity was not paralleled in human airway tissue, which may explain its failure in clinical studies (figure 5B).

**DISCUSSION**

Inhaled β2 adrenoceptor agonists are currently the gold standard bronchodilators prescribed to patients with respiratory diseases such as asthma and COPD. While long- and short-acting β agonists help to provide patients with short-term relief from airflow limitation, they do little to treat the underlying pathology. Furthermore, since the introduction of LABAs, there has been increasing concern about their safety, particularly when used as monotherapy.4 For these reasons, the search is on for
alternative bronchodilator therapies which have an increased safety profile. Identification of a safe therapeutic agent which also possesses anti-inflammatory activity would make for an extremely attractive alternative to LABAs.

PGE2 causes relaxation of animal17–19 isolated airway smooth muscle. Inhaled PGE2 is a bronchodilator in animals,10 mice and humans, and it has been suggested that EP2 receptor activation is responsible for this activity.16 In contrast, the data from human tissue studies clearly showed that PGE2-induced relaxation is mediated via the EP4 (selective EP4 receptor agonist) and not the EP3 receptor. This conclusion is based on the in vitro relaxant activity of a safe therapeutic agent (AH13205) with a promising preclinical profile did not appear to have any bronchodilator activity in man.16 Recently, however, improved tools have become available (selective ligands and prostanoid receptor-deficient mice) so, in the light of the issues with current bronchodilators, it seemed pertinent to revisit this area of research.

To investigate which receptor PGE2 acts to cause airway smooth muscle relaxation, a range of selective tools were tested on constricted isolated trachea tissue from guinea pigs, mice, monkeys, rats and humans. In all species PGE2 caused a concentration-dependent relaxation of airway smooth muscle. Experiments using selective ligands on guinea pig, monkey and mouse tissue identified the EP2 receptor as mediating this response, which is consistent with previous studies.16–18 This was further confirmed using mice deficient in individual prostanoid receptors, in that the response to PGE2 present in wild-type animals was substantially diminished in 
P2fertg2–/– mice, again confirming previous data.19–30 In contrast, but consistent with previous data, PGE2-induced relaxation of rat isolated tracheal smooth muscle was mediated via activation of the EP3 receptor.31

In contrast, the data from human tissue studies clearly showed that PGE2-induced relaxation is mediated via the EP4 and not the EP3 receptor. This conclusion is based on the in vitro relaxant activity of the selective EP4 receptor agonist (ONO-AE1-329) and the lack of activity of the selective EP2 receptor agonists (ONO-AE1-259, AH13205) in human airways. A role for the EP4 receptor was also substantiated by the lack of effect of AH6809 (EP1/EP2/DP receptor antagonist) and the effectiveness of the EP3 receptor antagonist (ONO-AE3-208) in inhbiting PGE2-induced relaxation of human airway smooth muscle. These data are in contrast to a previous publication describing a role for the EP2 receptor in PGE2-induced relaxation of human airway smooth muscle.17 However, there are some differences between our studies and previous ones which, in the main, can be explained by the lack of selectivity of the tools available at the time the previous studies were carried out. Compared with the study by Nore et al.,17 our study has benefited from the use of optimised, more potent and selective agonists (EP2 receptor agonist AH13205) with a promising preclinical profile.
Table 1 Prostanoid EP receptor agonist and antagonist affinities

<table>
<thead>
<tr>
<th>Ligand</th>
<th>Action</th>
<th>Affinity</th>
<th>Units</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Agonist</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP$_1$</td>
<td>ONO-D1-004</td>
<td>Full agonist</td>
<td>6.8 (mouse)</td>
<td>pKi 34</td>
</tr>
<tr>
<td>EP$_2$</td>
<td>AH 13205</td>
<td>Full agonist</td>
<td>6 (human)</td>
<td>pKi 35</td>
</tr>
<tr>
<td></td>
<td>ONO-AE1-259</td>
<td>Full agonist</td>
<td>8.5 (mouse)</td>
<td>pKi 34</td>
</tr>
<tr>
<td>Butaprost</td>
<td>Full agonist</td>
<td>5.9—7.0 (human)</td>
<td>pKi 24</td>
<td></td>
</tr>
<tr>
<td>Misoprostol</td>
<td>Full agonist</td>
<td>5.0 (human)</td>
<td>pKi 24</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ONO-AE-248</td>
<td>Full agonist</td>
<td>5.4 (mouse)</td>
<td>pKi 34</td>
</tr>
<tr>
<td></td>
<td>ONO-AE1-329</td>
<td>Full agonist</td>
<td>5.7 (mouse)</td>
<td>pKi 34</td>
</tr>
<tr>
<td>EP$_3$</td>
<td>Misoprostol</td>
<td>Full agonist</td>
<td>6.5 (human)</td>
<td>pKi 24</td>
</tr>
<tr>
<td>Butaprost</td>
<td>Full agonist</td>
<td>5.8 (human)</td>
<td>pKi 24</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ONO-AE-248</td>
<td>Full agonist</td>
<td>8.1 (mouse)</td>
<td>pKi 34</td>
</tr>
<tr>
<td>EP$_4$</td>
<td>ONO-AE1-329</td>
<td>Full agonist</td>
<td>8.0 (mouse)</td>
<td>pKi 24</td>
</tr>
<tr>
<td>Misoprostol</td>
<td>Full agonist</td>
<td>5.3 (human)</td>
<td>pKi 24</td>
<td></td>
</tr>
<tr>
<td>Butaprost</td>
<td>Full agonist</td>
<td>4.7 (human)</td>
<td>pKi 24</td>
<td></td>
</tr>
<tr>
<td><strong>Antagonist</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP$_1$</td>
<td>AH6809</td>
<td>Antagonist</td>
<td>5.9 (human)</td>
<td>pKi 24</td>
</tr>
<tr>
<td>EP$_2$</td>
<td>AH6809</td>
<td>Antagonist</td>
<td>5.9 (human)</td>
<td>pKi 24</td>
</tr>
<tr>
<td>EP$_4$</td>
<td>AH23848</td>
<td>Antagonist</td>
<td>4.9—5.6 (human)</td>
<td>pKi 24</td>
</tr>
<tr>
<td></td>
<td>ONO-AE3-208</td>
<td>Antagonist</td>
<td>8.9 (mouse)</td>
<td>pKi 26</td>
</tr>
<tr>
<td>GWA27568</td>
<td>Antagonist</td>
<td>7.0—7.1 (human)</td>
<td>pKi 25</td>
<td></td>
</tr>
</tbody>
</table>

selective compounds could potentially be the next generation of bronchodilators identified since the introduction of $\beta_2$ adrenoceptors and anticholinergics more than half a century ago.

Acknowledgements We would like to thank Nicole Dale for her assistance with some of the Cynomolgus (Cyno) monkey tissue experiments.

Funding The research project and SAM were funded by a project grant from the Medical Research Council (MRC) UK (G0800198). MAB was funded by a grant from the MRC (G0800198). DLC was funded by an MRC project grant Experimental Medicine Grant (G050209). The human tissue experiments in this study were undertaken with the support of the NIHR Biomedical Research Unit in Advanced Lung Disease at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London and partly funded by the NIHR Biomedical Research Unit funding scheme. JB was funded by a Studentship from a Capacity Building Award in Integrative Mammalian Biology funded by BBSRC, BPS, HFCE KTN and MRC.

Competing interests None.

Patient consent Obtained.

Ethics approval This study was conducted with the approval of the Royal Brompton and Harefield ethics committees.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


